拉丁美洲的共识是在牛皮中逐渐减少生物疗法
Angela María Londoño-García1, Juan Raúl Castro-Ayarza2, Manuel Darío Franco Franco3
1Dermatology Postgraduate Program, Faculty of Medicine, CES University, Medellin, Colombia.
Anais brasileiros de dermatologia
|June 24, 2025
概括
治疗牛皮的生物疗法对患有低疾病活性或缓解的患者是安全有效的. 这种方法优化了生物利用,特别是在资源有限的环境中.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 生物治疗对于牛皮是有效的,但存在风险和高成本.
- 由于长期的不良影响和经济负担,特别是拉丁美洲,正在探索减速生物制剂.
- 科学兴趣存在于逐渐减少生物药物的活性或缓解低疾病的患者.
研究的目的:
- 建立基于专家共识的建议,针对成人牛皮患者的个性化和有效的生物药物剂量逐渐减少.
- 引导皮肤科医生优化牛皮的生物疗法.
主要方法:
- 系统的文献审查,其次是修改后的Delphi方法.
- 由拉丁美洲皮肤科医生和一个独立的方法团队开发的共识.
- 关键主题包括治疗目标,逐渐缩减策略,监测和故障管理.
主要成果:
- 在五个一般原则和13个关于牛皮生物学逐渐减少的建议上达成共识.
- 建议为标准,战略,监测和实施提供科学支持.
- 专家小组提供了关于管理逐渐衰减故障的指导.
结论:
- 生物缓解是有效和安全的牛皮患者与稳定的低疾病活动或缓解.
- 这种拉丁美洲的共识促进了合理和最佳的生物利用.
- 建议强调个性化患者护理和应用最佳临床实践.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
210
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
210
01:28Drug Therapy
107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
107
01:29Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
01:26COPD: Management Using Bronchodilators and Corticosteroids
329
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
329
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278